Cancer treatment by electroporation method

A clinical trial to evaluate using electroporation system for treatment purposes and drug delivery to the tumor

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190904044697N8

Enrollment

Registered

2022-10-02

Start date

2022-10-01

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Malignant cancer with solid tumor. Condition 2: Benign tumor with solid mass. Condition 3: Malignant cancer with solid tumor. Condition 4: Benign tumor with solid mass. Condition 5: Malignant cancer with solid tumor. Condition 6: Malignant cancer with solid tumor. Condition 7: Malignant cancer with solid tumor. Condition 8: Malignant cancer with solid tumor. Condition 9: Malignant cancer with solid tumor. Condition 10: Malignant cancer with solid tumor. Condition 11: Malignant cance

Interventions

Intervention 1: ABC Intervention group: Receiving electroporation in addition to the usual treatment. Definition of intervention: In cases where the tumor is inoperable, the patient will be assigned i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancer patients who have different types of cancer with solid tumors. cancer stage IA, IB, IIA, IIB, IIIA, IIIB, IV (Karnofsky Score = ??) Patients with different types of benign and malignant tumors

Exclusion criteria

Exclusion criteria: Pregnancy Coagulation disorder (INR more than 1.5 times control) Platelets less than 100,000 Anemia (hemoglobin less than 10) Serious acute infection Having an implanted pacemaker, defibrillator or deep brain stimulator or cardiac arrhythmias.

Design outcomes

Primary

Measure	Time frame
Tumor size. Timepoint: Every two weeks. Method of measurement: Imaging modalities (Conventional ultrasound and especially Doppler ultrasound, MRI and CT scan).;Clinical and quality of life changes. Timepoint: Every week. Method of measurement: Investigating of Clinical Manifestation.;Tumor cell death. Timepoint: every three month. Method of measurement: Immunostaining, Immunohistochemistry, H&E.;Metastasis to other organs. Timepoint: Every 6 month. Method of measurement: Imaging by MRI, CT or PET scan.	—

Measure

Time frame

Tumor size. Timepoint: Every two weeks. Method of measurement: Imaging modalities (Conventional ultrasound and especially Doppler ultrasound, MRI and CT scan).;Clinical and quality of life changes. Timepoint: Every week. Method of measurement: Investigating of Clinical Manifestation.;Tumor cell death. Timepoint: every three month. Method of measurement: Immunostaining, Immunohistochemistry, H&E.;Metastasis to other organs. Timepoint: Every 6 month. Method of measurement: Imaging by MRI, CT or PET scan.

—

Secondary

Measure	Time frame
Quality Of Life. Timepoint: 90 days. Method of measurement: Questionnaire about quality of life indicators based on EORTC QLQ-C30.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Abdolahad

Tehran University of Medical Sciences

m.abdolahad@ut.ac.ir+98 21 8802 8367

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026